Bharat Biotech Rejects Study That Claimed Covaxin Less Effective Than Covishield


New Delhi, June 09: Bharat Biotech has categorically rejected a recent study that claimed that Covaxin is significantly less effective against the B.1.617.2 variant, the strain largely responsible for the ferocious second wave of the pandemic in the country.

The company also dismissed claims that its Covaxin is less effective than Serum Institute of India’s Covishield.